Discovery of OATD-01 , a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis.
Koralewski, R., Dymek, B., Mazur, M., Sklepkiewicz, P., Olejniczak, S., Czestkowski, W., Matyszewski, K., Andryianau, G., Niedziejko, P., Kowalski, M., Gruza, M., Borek, B., Jedrzejczak, K., Bartoszewicz, A., Pluta, E., Rymaszewska, A., Kania, M., Rejczak, T., Piasecka, S., Mlacki, M., Mazurkiewicz, M., Piotrowicz, M., Salamon, M., Zagozdzon, A., Napiorkowska-Gromadzka, A., Bartlomiejczak, A., Mozga, W., Dobrzanski, P., Dzwonek, K., Golab, J., Nowotny, M., Olczak, J., Golebiowski, A.(2020) J Med Chem 63: 15527-15540
- PubMed: 33078933 
- DOI: 10.1021/acs.jmedchem.0c01179
- Primary Citation of Related Structures:  
6ZE8 - PubMed Abstract: 
Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are the enzymatically active chitinases that have been implicated in the pathology of chronic lung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis ...